ICE Bioscience Posters

Language / 语言


Download

Degrader-antibody conjugates (DACs) represent a promising modality for cancer therapy, integrating a tumor-targeting antibody, a protein degrader payload, and a chemical linker into a single molecule. This design combines antibody-mediated tumor specificity with the degrader's ability to eliminate disease-associated proteins. To accelerate DAC development, ICE Bioscience has established a comprehensive evaluation platform enabling end-to-end characterization and assessment of DACs, from in vitro profiling to in vivo pharmacology.


Contact Us

We value your inquiries and are here to provide you with tailored solutions for your drug discovery and development needs. Whether you have questions, require more information, or are interested in discussing potential collaborations, our team of experts is just a message away.
Feel free to reach out to us.

We are a CRO service organization, not a hospital




Get a quote

Go top